 "pharma companies")
Indian pharmaceutical firms are upbeat about the success they had in 2017 — 300 generic drug approvals (an all-time high) from the US Food and Drug Administration (FDA).
However, the share of US business in the overall revenue of big pharma firms shrank in 2016-17 and in the first half of 2017-18, data shows. And, the trend is likely to continue for the next few quarters before the benefit from new drug launches start to accrue.
There is usually a time gap of 6-12 months from the date of the approval to the date of billing (after a
However, the share of US business in the overall revenue of big pharma firms shrank in 2016-17 and in the first half of 2017-18, data shows. And, the trend is likely to continue for the next few quarters before the benefit from new drug launches start to accrue.
There is usually a time gap of 6-12 months from the date of the approval to the date of billing (after a
